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Abstract 
Background: In 2012, the first dengue virus outbreak was reported on the Portuguese island of Madeira with 1080 
confirmed cases. Dengue virus of serotype 1 (DENV-1), probably imported from Venezuela, caused this outbreak with 
autochthonous transmission by invasive Aedes aegypti mosquitoes.
Results: We investigated the seroprevalence among the population on Madeira Island four years after the outbreak. 
Study participants (n = 358), representative of the island population regarding their age and gender, were enrolled in 
2012 in a cross-sectional study. Dengue antibodies were detected with an in-house enzyme-linked immunosorbent 
assay (ELISA) using the dimer of domain III (ED3) of the DENV-1 envelope protein as well as commercial Panbio indi-
rect and capture IgG ELISAs. Positive ELISA results were validated with a neutralization test. The overall seroprevalence 
was found to be 7.8% (28/358) with the in-house ELISA, whereas the commercial DENV indirect ELISA detected IgG 
antibodies in 8.9% of the individuals (32/358). The results of the foci reduction neutralization test confirmed DENV-1 
imported from South America as the causative agent of the 2012 epidemic. Additionally, we found a higher sero-
prevalence in study participants with an age above 60 years old and probable secondary DENV infected individuals 
indicating unreported dengue circulation before or after 2012 on Madeira Island.
Conclusions: This study revealed that the number of infections might have been much higher than estimated from 
only confirmed cases in 2012/2013. These mainly DENV-1 immune individuals are not protected from a secondary 
DENV infection and the majority of the population of Madeira Island is still naïve for DENV. Surveillance of mosquitoes 
and arboviruses should be continued on Madeira Island as well as in other European areas where invasive vector 
mosquitoes are present.
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Background
Dengue fever is the most widespread mosquito-borne 
viral disease causing an annual estimated 390 million 
infections [1] and 25,000 deaths [2]. Infection by any one 
of four antigenically distinct serotypes of dengue virus 
(DENV) can lead to symptoms including high fever or 
more severe disease with haemorrhage and plasma leak-
age. However, the majority (~80%) of infections results in 
a mild or subclinical outcome [3].
The virus is mainly transmitted by the mosquito spe-
cies Aedes aegypti, inhabiting the tropics and subtrop-
ics, but can also be transmitted by Ae. albopictus, which 
is an invasive species present in several European coun-
tries [4, 5]. Due to the increasing number of imported 
DENV infections [6, 7], there is a growing likelihood of 
autochthonous infections where competent vectors are 
present. Such autochthonous transmission of DENV 
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in regions with a naïve population has occurred inter-
mittently in France [8–10], Croatia [11, 12] and the 
USA [13, 14] over the past decade. Furthermore, Japan 
recently experienced an unprecedented epidemic in 
Tokyo [15, 16]. However, Europe has not witnessed a 
large dengue outbreak since the epidemic in Greece in 
1927/28 [17].
In September 2012, a unique European dengue out-
break occurred on Madeira Island, the larger of the two 
inhabited islands of the Portuguese autonomous region 
in the Atlantic Ocean. Madeira has been classified as 
having a Mediterranean climate, meaning it has mild 
year-round temperatures; the average annual tempera-
ture at the weather station of the capital city of Funchal 
was 19.6  °C for the period 1980–2010. On the highest 
windward slopes of Madeira, rainfall exceeds 1250 mm 
per year, mostly falling between October and April 
(according to the Meteorology Institute of Portugal, 
IPMA). The dengue epidemic resulted in 2168 prob-
able cases and 1080 confirmed infections from Sep-
tember 2012 to March 2013, affecting mainly residents 
from Funchal and the neighbouring provinces, Câmara 
de Lobos, Sao Martinho and Caniço [18]. The majority 
of the ≈270,000 inhabitants of this main island live on 
the south coast around the capital city of Funchal. In 
contrast to the small autochthonous dengue outbreaks 
on the European mainland, the outbreak in Madeira 
was spread by Ae. aegypti mosquitoes, which were first 
reported to be present on the island in 2004 [19]. As 
this was the first dengue epidemic that hit the Portu-
guese island, the population of Madeira was naïve for 
DENV infections. The DENV-1 serotype imported 
from Venezuela in South America and belonging to 
genotype V was believed to have been responsible for 
the outbreak [20, 21].
This study was conducted to investigate the seropreva-
lence among the population on Madeira Island and thus 
the actual extent of the dengue epidemic. We aimed to 
verify DENV-1 as the causative agent of the epidemic by 
performing foci reduction neutralization tests (FRNT) 
against all four DENV serotypes, and additionally against 
a DENV-1 genotype V isolate originally isolated in 2009 
in French Guiana [22]. A secondary objective was the 
evaluation of an in-house enzyme-linked immuno-sorb-
ent assay (ELISA) against a commercial indirect ELISA 
and the neutralization test, the gold standard for sero-




Serum samples from inhabitants of Madeira Island were 
collected in 2016. The minimum number of participants 
was estimated to be representative of the Madeira popu-
lation in 2012 (258,686 inhabitants) regarding all ages and 
both genders. The total number of participants for this 
seroprevalence study for the 235,233 people above the 
age of 10 years-old (study age range: 11–92 years), strati-
fied into gender and decennial age group, was calculated 
as previously described, applying the formula from Luiz 
& Magnanini [23]. Given that there were 1080 DENV 
confirmed cases during the 2012/2013 outbreak [18] and 
based on the assumption that only 20% infections led to 
symptomatic dengue fever cases, an estimated 5400 peo-
ple might actually have had dengue during the epidemic 
and the probable prevalence rate of viral infection would 
be 2.1%. Therefore, the minimum sample size was cal-
culated to be 237 participants (197 + 20% reserves), fol-
lowing the age/gender distribution shown in Additional 
file 2: Table S1.
The participants were recruited by convenience sam-
pling at the Henriques de Gouveia laboratory and the 
Madeira Medical Centre among patients coming for rou-
tine blood analyses in November in 2015. After present-
ing the purpose of our study, each volunteer who agreed 
to participate filled out a questionnaire with personal 
data and relevant health information: age, gender, weight, 
county of residence, history of travel to dengue endemic 
countries and history of yellow fever and Japanese 
encephalitis vaccination. Blood samples were collected 
from each participant using BD Vacutainer tubes, and 
one extra-tube using a BD Vacutainer SST II Advance 
8.5  ml was collected for the purpose of the study. The 
total blood volume was collected according to body 
weight of the participant as previously described [24]. On 
the day of collection, the blood samples dedicated to the 
study were centrifuged and an aliquot of 300 µl of serum 
of each sample was taken. All the samples were frozen 
and stored at -20 °C until laboratory analyses.
Enzyme‑linked immunosorbent assays
Both of the commercial Panbio ELISAs (Alere Inc., 
Waltham, MA, USA), Dengue IgG indirect ELISA and 
Dengue IgG capture ELISA, were performed according 
to the manufacturer’s instructions [25, 26]. The Panbio 
Dengue IgG indirect ELISA is used for the qualitative 
detection of IgG antibodies to DENV antigens of all 
four serotypes, whereas the Panbio Dengue IgG capture 
ELISA is used specifically for the qualitative detection of 
IgG antibodies in secondary DENV infections [25]. The 
latter is achieved by a higher cut-off value for positive 
results [27]. This testing strategy of using both commer-
cial Panbio ELISAs allowed not only the detection of pre-
vious DENV infection within the population of Madeira 
Island, but also the exploration of possible unreported 
secondary DENV infections. The in-house ELISA test is 
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an indirect assay developed at Institut Pasteur and uses 
the stabilized dimer of domain III (ED3) of the DENV-1 
envelope protein for the detection of IgG antibodies 
against DENV in human serum [28].
The ELISA was performed in 96-well plates (Greiner 
Bio One, Kremsmünster, Austria) with a 100 µl/well pro-
cessing volume. The plates were coated overnight at 4 °C 
with 100 µl of recombinant antigen diluted to 0.3 µg/ml in 
PBS (Sigma-Aldrich, Steinheim, Germany). The next day 
the coated plates were washed with PBS + 0.1% Tween 20 
(PBS-T) and then incubated for 1 h at 37 °C with 100 µl/
well of blocking buffer (PBS-T + 5% low-fat dried milk). 
Subsequently, the plates were washed with PBS-T and 
100  µl serum samples diluted 1:100 in blocking buffer 
were added to wells in duplicate. The plates were incu-
bated for 1  h at 37  °C. Next, serum dilutions were dis-
carded, and plates were washed four times with PBS-T. 
Then, 100  µl of goat horseradish peroxidase-conjugated 
anti-human IgG antibody (Sigma-Aldrich) diluted 1:1000 
in blocking buffer was added to each well and incubated 
for 1  h at 37  °C. Afterwards, plates were washed four 
times with PBS-T and 100  µl TMB substrate (Sigma-
Aldrich) was added to each well and left for 10–15 min. 
The colour reaction was stopped by adding 100 µl/well of 
0.5 N sulfuric acid and the optical density was measured 
at 450 nm with an Infinite 200 PRO NanoQuant spectro-
photometer (Tecan, Männedorf, Switzerland).
Cell lines for viral growth and neutralization studies
The monkey cell line LLC-MK2 was used for the detec-
tion of neutralizing antibodies via a foci reduction neu-
tralization test [29]. Cells were cultivated in Dulbecco’s 
modified Eagle medium (DMEM; Sigma-Aldrich) sup-
plemented with 10% fetal bovine serum (FBS; Gibco, 
Gaithersburg, MD, USA) and 100 U/ml penicillin-strep-
tomycin (Gibco) at 37  °C and in a 5%  CO2 atmosphere. 
All viruses were grown in Ae. albopictus C6/36 cells and 
harvested from the supernatant. These mosquito cells 
were cultured in Leibovitz 15 medium (Sigma-Aldrich) 
supplemented with 10% FBS, 1% L glutamine (Gibco), 
10% tryptose-phosphate (Gibco) and 100  U/ml penicil-
lin-streptomycin at 28 °C.
Viruses
The reference viruses used for the neutralization test were 
the following: DENV-1 Hawaii (GenBank: AF425619), 
DENV-2 New Guinea C (GenBank: AF038403), DENV-3 
strain H87 (GenBank: M93130), DENV-4 H241 (Gen-
Bank: AY947539) and JEV strain Nakayama (GenBank: 
EF571853). As no DENV-1 isolate from the Madeira epi-
demic was available, we used a virus that was isolated 
from a patient in French Guiana in 2009 (FGU 2009; 
GenBank: MH279620) that belongs to genotype V [22] 
(Additional file 3: Figure S1). The recombinant DENV-1 
ED3 protein was produced based on the DENV-1 strain 
FGA/89 (accession no. AF226687) [28].
Foci reduction neutralization test
The FRNT micro-neutralization assay, used as the gold 
standard, determined the level of neutralizing antibodies 
against different viruses. A subset of sera was tested by 
FRNT including (i) all sera formerly tested positive with 
at least one of the above mentioned ELISAs (n = 32); (ii) 
sera with an undetermined ELISA result (n = 3); and (iii) 
sera with negative results in all ELISAs randomly selected 
and representing 10% of the total study population, with 
similar numbers of sera for each age group (n = 36). The 
serum samples were analysed by FRNT as previously 
described [30], but modified by using LLC-MK2 cells and 
virus-specific polyclonal mouse hyperimmune ascites 
fluids (Institut Pasteur in Cambodia). Neutralization was 
defined as the serum dilution that induced a 90% reduc-
tion in the number of virus-induced foci (foci reduction 
neutralization test 90%;  FRNT90) compared to controls 
(virus alone and flavivirus-negative control serum alone) 
and was calculated via log probit regression analysis 
(SPSS for Windows v.16.0; SPSS Inc., Chicago, USA). The 
first serum dilution used for the assay was 1:10 which 
resulted in a final in-test dilution of 1:20 after adding an 
equivalent volume of virus. Subsequently, the lower limit 
of quantification for the  FRNT90 titer was defined as 20, 
which follows the WHO recommendations for flavivi-
rus FRNTs [31]. The DENV that induced at least a 4-fold 
higher titer compared to the other DENVs determined 
the DENV serotype responsible for the dengue infection.
Statistical analysis
Risk factor analysis of the association of age (continu-
ous), gender, yellow fever vaccination (yes/no), travel his-
tory outside of Madeira (yes/no) and geographical site 
(11 districts) on dengue seropositivity using the results 
from the indirect Panbio IgG was performed by fitting 
a generalized linear model with binomial error struc-
ture (i.e. logistic regression) using GenStat 15th Edition, 
(VSN International Ltd., Hemel Hempstead, UK). Wald 
test in the context of this logistic regression was used to 
determine whether a certain predictor variable was sig-
nificant or not. Wald statistics, which approximate to a 
Chi-square distribution, are given. A dispersion param-
eter was estimated to account for over-dispersion in the 
data. There were only two individuals with JEV vaccina-
tion and therefore this variable was not included in the 
analysis. Mean  FRNT90 titers were compared using the 
2-tailed Mann-Whitney test to determine if differences 
were significant. The agreement of the FRNT results 
with the results of the diverse ELISAs was performed 
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via Cohen’s kappa test. All statistical analyses were per-
formed with a significance level of α = 0.05.
An estimated number of total infections was calculated 
by multiplying the number of people of a determined age 
group (Additional file  2: Table  S1) by the proportion of 
seropositive results of that age group in the test popula-
tion. The process was repeated for all the pre-determined 
age groups and summed to give the estimated num-
ber of infections. For example, if we had 15,000 people 
aged from 20–29 on Madeira Island at the time, and we 
had collected 100 blood samples from people of that age 
group of which 15 had a positive result, then we estimate 
that 2250 people of that age group have been infected by 
dengue. This calculation was carried out for every stud-
ied age group and then summed to generate an overall 
estimated number of infections.
Results
Study population
The study enrolled 358 individuals aged from 11 to 92 
(mean age: 49) and a male:female ratio of 0.61 (Table 1). 
The study included residents from all 11 districts of 
Madeira although the majority of the study participants 
resided in Funchal (229/358, 64.0%). In total, 8.7% of the 
study participants (31/358) self-reported a former vac-
cination against the yellow fever virus (YFV), and 31.8% 
(114/358) had travelled to DENV endemic countries. 
Only two participants were previously vaccinated against 
Japanese encephalitis virus (JEV).
Seroprevalence
The dengue seroprevalence of the study participants 
was tested by in-house DENV IgG indirect ELISA using 
dimer of Domain III (ED3) of the DENV-1 envelope pro-
tein and the DENV IgG indirect ELISA from Panbio. In 
total, the in-house ELISA detected 7.8% (28/358) of the 
study participants as positive, whereas the commercial 
DENV indirect ELISA detected IgG antibodies in 8.9% 
of the individuals (32/358; Table  2). For three samples 
the result of the indirect Panbio ELISA was undeter-
mined. A subset of 71 sera was tested by FRNT including 
all sera with a positive (n = 36) or undetermined (n = 3) 
result in any of the two indirect ELISAs (Additional file 4: 
Table S2) and 32 sera with negative results in all ELISAs. 
Individuals were considered positive for DENV antibod-
ies if they showed a  FRNT90 titer ≥ 20 for one or more 
DENV reference strains. Based on these criteria, 28 study 
participants were found positive for DENV neutralizing 
antibodies (Table 2).
Among the DENV seropositive samples, the DENV 
capture IgG ELISA from Panbio designed to identify 
secondary dengue infection detected five positive indi-
viduals (5/28, 17.9%). Additionally, four people (4/28, 
14.3%) showed inconclusive results and therefore the 
dengue immune status could not be determined with 
this assay. Based on these results, most of the seroposi-
tive study participants (19/28, 67.8%) were considered 
to have had a primary DENV infection.
Seropositive individuals were found in only five of 
the eleven districts of Madeira, largely reflecting sam-
pling effort. Most of the seropositive individuals (20/28, 
71.4%) were residents of Funchal, with ever decreas-
ing numbers in the other Southern districts (Ponta do 
Sol, Ribeira Brava, Câmara de Lobos and Santa Cruz) 
(Fig. 1). We detected only two cases from the north, one 
from Porto Moniz and one from Sao Vicente (Table 1).
Risk factor analysis of the indirect Panbio ELISA sero-
positivity revealed no significant association with gen-
der (Wald test: χ2 = 0.28, df = 1, P = 0.595), yellow fever 
vaccination (Wald test: χ2 = 0.72, df = 1, P = 0.397), 
Table 1 Demographic characteristics of study participants
a Dengue seropositive patient identified by at least one ELISA assay and 
confirmed with seroneutralization assay (FRNT)
b To dengue endemic countries
Abbreviations: DENV, dengue virus; YFV, yellow fever virus






Total number 28 (7.8) 330 (92.2) 358 (100)
 Male 11 (8.1) 125 (91.9) 136 (38.0)
 Female 17 (7.7) 205 (92.3) 222 (62.0)
Median age (years) 57.5 49 49
 10–19 0 (0) 19 (100) 19 (5.3)
 20–29 3 (7.9) 35 (92.1) 38 (10.6)
 30–39 3 (4.8) 59 (95.2) 62 (17.3)
 40–49 6 (9.8) 55 (90.2) 61 (17.0)
 50–59 3 (4.2) 68 (95.8) 71 (19.9)
 60+ 13 (12.1) 94 (87.9) 107 (29.9)
Travel  historyb 9 (7.9) 105 (92.1) 114 (31.8)
No travel  historyb 19 (7.8) 225 (92.2) 244 (68.2)
YFV vaccination 3 (9.7) 28 (90.3) 31 (8.7)
No YFV vaccination 25 (7.6) 302 (92.4) 327 (91.3)
Funchal 20 (8.7) 209 (91.3) 229 (64.0)
Câmara de Lobos 1 (4.5) 21 (95.5) 22 (6.1)
Santa Cruz 3 (6.1) 46 (93.9) 49 (13.7)
Sao Vicente 1 (16.7) 5 (83.3) 6 (1.7)
Porto Moniz 1 (50) 1 (50) 2 (0.6)
Machico 0 (0) 8 (100) 8 (2.2)
Ribeira Brava 0 (0) 8 (100) 8 (2.2)
Calheta 0 (0) 6 (100) 6 (1.7)
Santana 0 (0) 4 (100) 4 (1.1)
Ponta do Sol 0 (0) 4 (100) 4 (1.1)
Porto Santo 0 (0) 2 (100) 2 (0.6)
Missing data 2 (11.1) 16 (88.8) 18 (5.0)
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travel history to DENV endemic countries (Wald test: 
χ2 = 0.01, df = 1, P = 0.94) or place of residence (Wald 
test: χ2 = 6.69, df = 10, P = 0.753). However, there was 
a significantly increased risk with increasing age (Wald 
test: χ2 = 12.57, df = 1, P < 0.001; odds ratio per year of age 
1.03; 95% CI: 1.01–1.05).
The seroprevalence results were extrapolated to obtain 
the estimated number of infections during the dengue 
outbreak. Based on the population in 2012 (total num-
ber of residents: 258,686) and the FRNT confirmed sero-
prevalence of 7.8%, the total number of infections was 
estimated to be 16,606 (95% binomial CI: 9221–41,303). 
Table 2 Comparison of serology results obtained with the different enzyme-linked immuno-sorbent assays used (n = 358) and the 
foci reduction neutralization test (n = 71)
a Subset of additional samples tested by FRNT
b FRNT90 titer ≥ 20
c Dengue reference strain
Abbreviations: DENV, dengue virus; ELISA, enzyme-linked immuno-sorbent assay; FRNT, foci reduction neutralization test







DENV-1 ED3 dimer ELISA (in-house) 28 (7.8) 330 (92.2) –
DENV IgG indirect ELISA (Panbio) 32 (8.9) 323 (90.3) 3 (0.8)
DENV IgG capture ELISA (Panbio) 5 (1.4) 349 (97.5) 4 (1.1)
n = 71a
DENV-1 ED3 dimer ELISA (in-house) 28 (39.4) 43 (60.6) –
DENV IgG indirect ELISA (Panbio) 32 (45.1) 36 (50.7) 3 (4.2)
DENV IgG capture ELISA (Panbio) 5 (7.1) 62 (87.3) 4 (5.6)
FRNTb 28 (39.4) 43 (60.6) –
 DENV-1c 24 (33.8) 47 (66.2) –
 DENV-2c 5 (7.0) 66 (93.0) –
 DENV-3c 5 (7.0) 66 (93.0) –
 DENV-4c 7 (9.9) 64 (90.1) –
 DENV-1 genotype V 27 (38.0) 44 (62.0) –
Fig. 1 Geographical distribution of the seroprevalence across Madeira Island. Districts with dengue seropositive study participants are shown in 
blue and the respective residences are marked with red dots. The map was created using QGIS 2.14.3 and the base layer data were obtained from 
DIVA GIS (http://www.diva-gis.org/gdata )
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The 60+ years old group contributed an estimated > 6000 
cases due to the high seroprevalence observed (12.1%; 13 
seropositive out of 107 study participants with an age of 
60+).
FRNT with DENV reference strains and DENV‑1 genotype V 
strain
A subset of 71 sera was tested by FRNT using all four 
dengue serotypes to measure the levels of neutralizing 
antibodies  (FRNT90 titer; Table  2) as well as the sero-
type. The DENV serotype was identified as the virus 
which induced the highest  FRNT90 titer. Overall, the 
FRNT using DENV reference strains detected 28 indi-
viduals with neutralizing antibodies; all these individu-
als formerly tested positive with at least one of the three 
describes ELISAs. None of the ELISA negative samples 
was detected positive with the FRNT. Among the 28 
FRNT positive samples, 24 (85.7%) were detected posi-
tive for neutralizing antibodies against DENV-1 reference 
strain. Among these, we identified 21 individuals with 
DENV-1 serotype (indicated by the highest  FRNT90 titer 
against DENV-1 reference strain compared to the other 
DENVs). Moreover, three study participants were identi-
fied with neutralizing antibodies against DENV-2 (n = 1), 
DENV-3 (n = 1) or DENV-4 (n = 1).
After using the reference strains for all four DENVs 
(DENV 1-4) we investigated further the immune response 
to DENV-1 genotype V strain, as this was the proposed 
cause of the 2012 outbreak in Madeira Island. Among 
the 71 sera tested by FRNT with a DENV-1 genotype 
V strain, we identified one study participant with a low 
 FRNT90 titer of 30 against this DENV-1 genotype V strain 
that was formerly negative against all four DENV refer-
ence strains (Additional file 4: Table S2). This increased 
the total number of FRNT positive study participants 
to 29 (Table 3, Fig. 2). Two other individuals were nega-
tive for antibodies against the DENV-1 reference strain 
but showed detectable levels of neutralizing antibodies 
against the DENV-1 genotype V strain  (FRNT90 titer of 
73 and 71, respectively). One of these also had neutral-
izing antibodies against DENV-3  (FRNT90 = 58); the 
other individual was also positive for both DENV-3 
 (FRNT90 = 24) and DENV-4  (FRNT90 = 81). 
Four study participants had similar  FRNT90 titers 
against two serotypes (one with DENV-1 + DENV-2, one 
with DENV-3 + DENV-4, two with DENV-1 + DENV-
4). The  FRNT90 titers for the DENV-1 reference strain 
(mean  FRNT90 = 201) of the seropositive sera (n = 29) 
were significantly higher than against DENV-2 (mean 
 FRNT90 = 13; Mann-Whitney U = 114.5, n1 = n2 = 29, 
P < 0.0001, two-tailed), DENV-3 (mean  FRNT90 = 12; 
Mann-Whitney U = 110, n1 = n2 = 29, P < 0.0001, 
two-tailed) and DENV-4 (mean  FRNT90 = 18; Mann-
Whitney U = 117, n1 = n2 = 29, P < 0.0001, two-tailed; 
Table  3, Fig.  2). The  FRNT90 titers against the geno-
type V (mean  FRNT90 = 444) were twice as high as 
the titers against the DENV-1 reference strain (mean 
 FRNT90 = 201) belonging to genotype I in the positive 
individuals (n = 29). As observed before with the DENV-1 
reference strain, the mean  FRNT90 titer against the 
DENV-1 genotype V strain was significantly higher than 
the mean neutralization titers against the other DENV 
serotypes (DENV-2: Mann-Whitney U = 42, n1 = n2 = 29, 
P < 0.0001, two-tailed; DENV-3: Mann-Whitney U = 39, 
n1 = n2 = 29, P < 0.0001, two-tailed; DENV-4: Mann-
Whitney U = 53.5, n1 = n2 = 29, P < 0.0001, two-tailed; 
Table 3, Fig. 2).
None of the 71 tested sera showed any detectable neu-
tralizing antibodies against JEV. The results of the 32 
serum samples formerly tested negative in both indirect 
ELISAs (in-house and Panbio) were confirmed nega-
tive by FRNT with all DENV reference strains and the 
DENV-1 genotype V isolate.
ELISAs in comparison to FRNT
The second objective of this study was the evaluation 
of the DENV-1 ED3 dimer indirect ELISA in compari-
son to the commercial IgG indirect ELISA from Panbio 
and the FRNT. This comparative analysis was done with 
a subset of 71 sera tested in all above mentioned assays. 
Within these, the in-house DENV-1 ED3 dimer indirect 
ELISA detected 28 (39.4%) positive individuals, whereas 
the commercial DENV indirect ELISA detected IgG anti-
bodies in 32 of the individuals (45.1%; Table 2). For three 
samples, the results with the Panbio indirect ELISA were 
undetermined. The FRNT confirmed 78.6% (22/28) of the 
positive results from the in-house indirect ELISA results 
and 90.6% (29/32) of the Panbio indirect ELISA positive 
results (Additional file 4: Table S2). Taking the FRNT as 
the gold standard assay, the in-house ELISA produced six 
Table 3 Mean neutralization titers for seropositive samples by 
foci reduction neutralization test (n = 29)
Abbreviations: 95% CI, 95% confidence interval; DENV, dengue virus; FRNT, foci 
reduction neutralization test
Virus used Positive samples with FRNT
Mean  FRNT90 95% CI
DENV-1 reference strain 201 127–275
DENV-1 genotype V strain 444 262–626
DENV-2 reference strain 13 5.5–21
DENV-3 reference strain 12 6–18
DENV-4 reference strain 18 6–31
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false positive and seven false negative results. The Pan-
bio indirect ELISA produced three false positive results. 
Interestingly, one individual who tested positive with 
the indirect Panbio ELISA was negative when tested by 
the in-house ELISA and the FRNT using DENV refer-
ence strains, but had detectable neutralizing antibodies 
against DENV-1 genotype V  (FRNT90 = 30). Including 
all 71 samples tested with FRNT, the DENV-1 in-house 
ELISA led to 58 congruent results (81.7%) with the 
FRNT (κ = 0.619; 95% CI: 0.433–0.806). The kappa test 
revealed 91.5% agreement (65/71 results) between the 
Panbio indirect ELISA and the FRNT (κ = 0.836, 95% CI: 
0.716–0.956).
The five individuals identified as having had a second-
ary DENV infection with the IgG capture ELISA from 
Panbio showed no significantly higher titers of neutral-
izing antibodies in the FRNT. However, these individu-
als with suspected secondary DENV infections had more 
often a broad neutralization pattern, where the FRNT 
analysis did not identify a single serotype but detected 
multiple serotypes. Three of these secondary infected 
individuals belong to the age group of 60+.
Discussion
The results of our dengue seroprevalence study on the 
population of Madeira Island are in agreement with 
investigations made during or directly after the outbreak. 
The extent of the outbreak and the fact that Madeira is a 
favourite tourist destination led to 81 exported cases to 
mainland Europe after returning from Madeira: 11 cases 
to mainland Portugal and 70 in other European coun-
tries [18] including Finland [32], Belgium [33], Romania 
[34], Germany and the UK [35]. Partial sequencing and 
phylogenetic investigations of autochthonous cases from 
Madeira and imported cases to other European countries 
identified DENV serotype 1 (DENV-1) genotype V as 
the causative agent of the outbreak [32, 36], highly likely 
imported from Venezuela [20, 34].
Our study using FRNT confirmed this suspicion, 
revealing that the concentration of neutralizing anti-
bodies was higher against genotype V than against the 
reference isolate of genotype I. DENV-1 genotype V is 
epidemiologically very important due to its broad distri-
bution in the Americas, Asia, Oceania and Africa over 
the last 75 years [37, 38], and because it can cause infec-
tions with a severe clinical outcome [39].
The distribution of the seropositive individuals found in 
this study confirmed the higher attack rate in the south-
ern districts, especially in Funchal, as reported after the 
ECDC outbreak investigation [18]. This is not surpris-
ing as the densities of both the human and Ae. aegypti 
populations are highest on the southern coastline. The 
high seroprevalence in individuals aged 60+ could be due 
to unreported previous exposure to DENV. This is sup-
ported by our findings that three out of the five identified 
secondary infections occurred in this age group.
We found neutralizing antibodies, mainly directed 
against DENV-1, in 7.8% of our study population, 
whereas the infection rate based on the 1080 confirmed 
cases of the outbreak was only 0.4% (and ~1% for prob-
able cases). A similarly high seroprevalence rate (5%) was 
observed in individuals without recollection of symp-
toms in the vicinity of the Tokyo Yoyogi Park outbreak 
that led to 162 confirmed cases [16]. A 7:1 ratio of sub-
clinical to symptomatic infection outcome is within the 
range previously observed [3, 40]. Due to the high num-
ber of subclinical or inapparent infections, especially in 
naïve populations, seroprevalence studies are important 
for risk assessment if DENV-1 re-emerges or if another 
DENV serotype is imported [3]. From our seroprevalence 
studies, global estimates of infection in the Madeira pop-
ulation suggest a very high number of individuals have 
been exposed to the virus during this relatively short epi-
demic. This is significant as secondary infections lead to 
an increase in severity of disease [41].
Overall, the cross-reactivity of DENV is not fully under-
stood and there are contrary findings. The specificity of 
antibodies is not directly correlated with their neutraliza-
tion capacity. Serotype-specific antibodies represent only 
a small fraction of the neutralizing antibodies [42] and 
cross-reacting antibodies contribute significantly to the 
neutralization capacity [43, 44]. Additionally, neutralizing 
antibodies are an important correlate for protection [45] 
but are not the only determining factor. Moreover, recent 
findings highlight the importance of the cellular immune 
response for protective immunity [46]. It is assumed that 
Fig. 2 Individual  FRNT90 titers of all FRNT positive study participants 
(n = 29). Mean  FRNT90 titers with standard error for FRNT positive 
samples. Overall, 28 samples were positive in the FRNT using the 
reference strains of DENV-1 (red), DENV-2 (blue), DENV-3 (green) and 
DENV-4 (yellow). An additional FRNT with DENV-1 genotype V (pink) 
added one more seropositive study participant. The dashed line 
indicates threshold of 20. Asterisks indicate the statistically significant 
different mean  FRNT90 titers between the DENV-1 reference strain 
and the DENV-1 genotype V strain with the other DENV serotypes 
(Mann-Whitney test, P < 0.0001)
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a primary DENV infection induces a short-term cross-
reacting immune response against all serotypes [47, 48], 
but no long-term protection against heterotypic second-
ary DENV infection [49]. However, there is long-term 
homotypic humoral immunity (e.g. DENV-1 antibod-
ies were found even 60  years after the infection [50]) 
although there are recent reports of homotypic DENV 
re-infections with a clinical outcome [51, 52]. Even cross-
protection across genotypes within one serotype varies, 
as is known for DENV-2 [53, 54] and DENV-3 [55]. On 
the other hand vaccination studies in macaques showed 
cross-protection between the two DENV-1 genotypes 
IV and V [56]. Cross-neutralization among the DENV-1 
genotypes was also observed in patients infected with 
genotype I or IV [57]. However, studies with mouse 
monoclonal antibodies against DENV-1 genotype II 
showed a reduced neutralization capacity against heter-
ologous genotypes [58]. Additionally, Shrestha et al. [58] 
investigated DENV-1 monoclonal antibodies from mice 
infected with DENV-1 genotype II and found only two 
out of 76 monoclonal antibodies that showed a strong 
neutralization against all five DENV-1 genotypes. Such 
partial lack of intra-serotype cross-neutralization can be 
explained by the high diversity of the DENV-1 serotype 
[59] and may explain our observed differences in neutral-
ization to genotypes I and V of DENV-1.
The second goal of this investigation was the evaluation 
of the previously developed ED3 dimer indirect ELISA 
[28]. This assay showed a good agreement of 81.7% with 
the gold standard for flavivirus serological diagnostics, 
the neutralization test, performed in this study as FRNT 
with DENV reference strains. The commercial indirect 
ELISA of Panbio showed 91.5% congruent results with 
the FRNT using samples from a non-flavivirus endemic 
area. This study demonstrates the feasibility of sero-
prevalence analysis with in-house ED3 dimer indirect 
ELISA. The lower sensitivity compared to the Panbio 
indirect ELISA and the FRNT could be explained by the 
use of the DENV-1 ED3 antigen alone and not in com-
bination with the respective antigens of the other sero-
types. A combined application of recombinant antigens 
for all four serotypes could lead to the detection of the 
individuals with more cross-reactive antibodies, as we 
observed study participants with FRNT serotypes other 
than DENV-1 and four individuals with similar titers of 
neutralizing antibodies against two serotypes. The strat-
egy of combining recombinant antigens of all four DENV 
serotypes has been already used successfully in diagnos-
tic assays [60–62]. Additionally, as described by Zidane 
et al. [28], the DENV-1 sequence used for the production 
of the DENV-1 ED3 antigen is closest to the PCP-consen-
sus sequence derived from 600 DENV strains including 
all four serotypes [63].
Further surveillance of invasive mosquitoes and vector-
borne diseases on Madeira Island is important not only 
regarding the still existing risk of (re-)emerging DENV, 
but also due to the high danger of importation of other 
arboviruses such as chikungunya or Zika. For the latter, 
a recent investigation by Jupille et  al. [64] showed that 
Ae. aegypti from Madeira Island are efficient vectors. 
The mosquito surveillance in Funchal observed increas-
ing populations from 2006 and 2008 [65] and the highest 
mosquito density around Funchal during the beginning 
of the DENV outbreak [66], likely due to mild climatic 
conditions.
However, our study has some limitations. For fur-
ther characterization of the immune response we used 
a DENV-1 genotype V isolated from a patient in French 
Guiana in 2009. This isolate belongs to the same geno-
type as the virus that was partially sequenced during 
the Madeira outbreak. Nevertheless, to our knowledge 
the Madeira virus was never isolated, which hindered 
the direct analysis of the immune response against this 
virus. Another limitation is that not all districts were 
represented equally. Most of the study participants were 
residents of Funchal, which might lead to an underrepre-
sentation of cases in the other districts.
Conclusions
We performed the first seroprevalence study after the 
DENV-1 outbreak on Madeira Island. We observed a pre-
dominant immune response against DENV-1, especially 
against genotype V, in seropositive study participants. 
Our study also revealed that the number of infections 
might have been much higher than estimated from only 
confirmed cases in 2012/2013, as we observed a seroprev-
alence of 7.8%. These mainly DENV-1 immune individu-
als are not protected from a secondary DENV infection 
and the majority of the population of Madeira Island is 
still naïve for DENV and other arboviruses. Therefore, 
the surveillance of mosquitoes and arboviruses should be 
continued on Madeira Island as well as in other European 
areas where invasive vector mosquitoes are present.
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